NZ554236A - Host-vector system for antibiotic-free cole1 plasmid propagation - Google Patents
Host-vector system for antibiotic-free cole1 plasmid propagationInfo
- Publication number
- NZ554236A NZ554236A NZ554236A NZ55423605A NZ554236A NZ 554236 A NZ554236 A NZ 554236A NZ 554236 A NZ554236 A NZ 554236A NZ 55423605 A NZ55423605 A NZ 55423605A NZ 554236 A NZ554236 A NZ 554236A
- Authority
- NZ
- New Zealand
- Prior art keywords
- plasmid
- protein
- rna
- gene
- expression
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 211
- 239000013598 vector Substances 0.000 title claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 246
- 230000014509 gene expression Effects 0.000 claims abstract description 85
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 83
- 108091030071 RNAI Proteins 0.000 claims abstract description 77
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 77
- 230000001580 bacterial effect Effects 0.000 claims abstract description 56
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 55
- 230000010076 replication Effects 0.000 claims abstract description 40
- 230000001105 regulatory effect Effects 0.000 claims abstract description 19
- 230000000295 complement effect Effects 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 101
- 239000003550 marker Substances 0.000 claims description 92
- 231100000331 toxic Toxicity 0.000 claims description 48
- 230000002588 toxic effect Effects 0.000 claims description 48
- 241000588724 Escherichia coli Species 0.000 claims description 32
- 108020004414 DNA Proteins 0.000 claims description 28
- 108700039887 Essential Genes Proteins 0.000 claims description 27
- 231100000518 lethal Toxicity 0.000 claims description 24
- 230000001665 lethal effect Effects 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 230000012010 growth Effects 0.000 claims description 18
- 210000003705 ribosome Anatomy 0.000 claims description 14
- 108091081024 Start codon Proteins 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 108010034634 Repressor Proteins Proteins 0.000 claims description 5
- 102000009661 Repressor Proteins Human genes 0.000 claims description 5
- 230000000754 repressing effect Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000009036 growth inhibition Effects 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- 101150055869 25 gene Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 description 55
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 53
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 53
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- 230000003993 interaction Effects 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- 230000006698 induction Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000013519 translation Methods 0.000 description 15
- 230000003115 biocidal effect Effects 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 101150089003 murA2 gene Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000003828 downregulation Effects 0.000 description 11
- 239000000411 inducer Substances 0.000 description 11
- 101100239088 Bacillus subtilis (strain 168) murAA gene Proteins 0.000 description 10
- 101100131847 Bacillus subtilis (strain 168) murAB gene Proteins 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 101150025333 murA gene Proteins 0.000 description 10
- 101150023205 murA1 gene Proteins 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 239000003184 complementary RNA Substances 0.000 description 9
- 108020005544 Antisense RNA Proteins 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000010354 integration Effects 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 210000003578 bacterial chromosome Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 101150061166 tetR gene Proteins 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000037440 gene silencing effect Effects 0.000 description 4
- 238000013383 initial experiment Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 101150025220 sacB gene Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 3
- 230000004570 RNA-binding Effects 0.000 description 3
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 108010046276 FLP recombinase Proteins 0.000 description 2
- 238000012366 Fed-batch cultivation Methods 0.000 description 2
- 108010036940 Levansucrase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241000701245 Paramecium bursaria Chlorella virus 1 Species 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 101100075995 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fma2 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 101150117187 glmS gene Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- ANVAOWXLWRTKGA-NTXLUARGSA-N (6'R)-beta,epsilon-carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-NTXLUARGSA-N 0.000 description 1
- 101710192508 30S ribosomal protein S2 Proteins 0.000 description 1
- 108050003931 30S ribosomal proteins Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000908115 Bolivar Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000722731 Carex Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 102000006465 DNA Restriction-Modification Enzymes Human genes 0.000 description 1
- 108010044289 DNA Restriction-Modification Enzymes Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108700034853 E coli TRPR Proteins 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100285515 Escherichia coli (strain K12) hokD gene Proteins 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 241000272186 Falco columbarius Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000029793 Isoleucine-tRNA ligase Human genes 0.000 description 1
- 101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101150064138 MAP1 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101100468245 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) relF gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101100443856 Streptococcus pyogenes serotype M18 (strain MGAS8232) polC gene Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108091029855 T44 RNA Proteins 0.000 description 1
- 101710120203 Tetracycline resistance determinant Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- DLRVVLDZNNYCBX-CAPXFGMSSA-N allolactose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)O1 DLRVVLDZNNYCBX-CAPXFGMSSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150027005 divIB gene Proteins 0.000 description 1
- 101150008507 dnaE gene Proteins 0.000 description 1
- 101150035285 dnaE1 gene Proteins 0.000 description 1
- 101150003155 dnaG gene Proteins 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 101150012763 endA gene Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 101150101609 ftsA gene Proteins 0.000 description 1
- 101150002100 ftsK gene Proteins 0.000 description 1
- 101150026421 ftsQ gene Proteins 0.000 description 1
- 101150111615 ftsZ gene Proteins 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 101150023479 hsdS gene Proteins 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000008531 maintenance mechanism Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 101150112095 map gene Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04022201 | 2004-09-17 | ||
| PCT/EP2005/054450 WO2006029985A2 (en) | 2004-09-17 | 2005-09-08 | Host-vector system for antibiotic-free cole1 plasmid propagation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ554236A true NZ554236A (en) | 2010-05-28 |
Family
ID=34926585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ554236A NZ554236A (en) | 2004-09-17 | 2005-09-08 | Host-vector system for antibiotic-free cole1 plasmid propagation |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060063232A1 (enExample) |
| EP (1) | EP1794299B1 (enExample) |
| JP (1) | JP5301832B2 (enExample) |
| KR (2) | KR101023066B1 (enExample) |
| CN (2) | CN101052722A (enExample) |
| AR (2) | AR050649A1 (enExample) |
| AU (1) | AU2005284136B2 (enExample) |
| BR (1) | BRPI0515436A (enExample) |
| CA (1) | CA2580009C (enExample) |
| IL (1) | IL181919A (enExample) |
| NZ (1) | NZ554236A (enExample) |
| TW (1) | TWI311152B (enExample) |
| WO (1) | WO2006029985A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327056D0 (en) * | 2003-11-20 | 2003-12-24 | Cobra Biolog Ltd | Plasmid maintenance |
| AU2008252990B2 (en) * | 2007-05-17 | 2015-01-15 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Method for producing a recombinant protein on a manufacturing scale |
| EP2152889B1 (en) * | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| WO2009011651A1 (en) * | 2007-07-16 | 2009-01-22 | Rvc Enterprise | Mutually suppressive gene/inhibitor combinations for non-antibiotic selection of recombinant strains |
| JP5538691B2 (ja) * | 2007-11-22 | 2014-07-02 | 独立行政法人科学技術振興機構 | Ｒｎａ−蛋白質相互作用モチーフを利用した蛋白質応答翻訳制御システム |
| EP2221371B1 (en) | 2007-11-22 | 2013-11-13 | Japan Science and Technology Agency | Translation regulation system in cell or artificial cell model by using low-molecular-weight rna |
| LT2432884T (lt) * | 2009-05-22 | 2016-11-10 | Merial, Inc. | Neturinti antibiotiko plazmidė |
| US20110269184A1 (en) | 2009-07-16 | 2011-11-03 | Boehringer Ingelheim Rcv Gmbh & Co. Kg | Method for controlling plasmid copy number in e.coli |
| WO2012082946A2 (en) * | 2010-12-14 | 2012-06-21 | The Regents Of The University Of California | Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations. |
| GB201021795D0 (en) * | 2010-12-21 | 2011-02-02 | Msd Biolog Uk Ltd | Expression Process |
| WO2014035457A1 (en) | 2012-08-29 | 2014-03-06 | Nature Technology Corporation | Dna plasmids with improved expression |
| US20150322439A1 (en) | 2012-11-19 | 2015-11-12 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
| CA3042391A1 (en) * | 2016-11-02 | 2018-05-11 | ArcherDX, Inc. | Methods of nucleic acid sample preparation for immune repertoire sequencing |
| CN107142272A (zh) * | 2017-06-05 | 2017-09-08 | 南京金斯瑞生物科技有限公司 | 一种控制大肠杆菌中质粒复制的方法 |
| WO2019057774A1 (en) | 2017-09-19 | 2019-03-28 | Deutsches Krebsforschungszentrum | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS |
| EP3456821B2 (en) | 2017-09-19 | 2024-01-24 | Deutsches Krebsforschungszentrum | Non-integrating dna vectors for the genetic modification of cells |
| EP4151735A1 (en) | 2018-03-21 | 2023-03-22 | Nature Technology Corporation | Viral and non-viral nanoplasmid vectors with improved production |
| JP7661015B2 (ja) * | 2020-06-12 | 2025-04-14 | ナガセヴィータ株式会社 | 目的タンパク質の製造方法 |
| WO2023166132A1 (en) * | 2022-03-04 | 2023-09-07 | Gen-H Genetic Engineering Heidelberg Gmbh | Microorganism strain for antibiotic-free plasmid-based fermentation and method for generation thereof |
| CN117187281A (zh) * | 2023-09-11 | 2023-12-08 | 云舟生物科技(广州)股份有限公司 | 一种无抗性质粒生产系统及其应用 |
| CN118028194B (zh) * | 2023-12-26 | 2024-09-06 | 浙江大学 | 基因组精简的恶臭假单胞菌菌株 |
| WO2025160245A1 (en) | 2024-01-25 | 2025-07-31 | Aldevron, L.L.C. | Viral and non-viral nanoplasmid vectors with improved production |
| WO2025231315A2 (en) | 2024-05-03 | 2025-11-06 | Aldevron, L.L.C. | Bacterial host strains |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9215541D0 (en) * | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5922583A (en) * | 1995-10-17 | 1999-07-13 | Biostar Inc. | Methods for production of recombinant plasmids |
| EP1195436A1 (en) | 2000-10-04 | 2002-04-10 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Expression vectors with modified ColE1 origin of replication for control of plasmid copy number |
| JP2004533827A (ja) * | 2001-05-17 | 2004-11-11 | アールフス・ユニバーシティー | 遺伝子治療用の改良されたベクター |
| SE0102204D0 (sv) * | 2001-06-21 | 2001-06-21 | Leif Isaksson | New method |
| CN1490056A (zh) * | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
| GB0327056D0 (en) | 2003-11-20 | 2003-12-24 | Cobra Biolog Ltd | Plasmid maintenance |
-
2005
- 2005-09-06 TW TW94130459A patent/TWI311152B/zh not_active IP Right Cessation
- 2005-09-08 KR KR20077007467A patent/KR101023066B1/ko not_active Expired - Lifetime
- 2005-09-08 CN CNA2005800377789A patent/CN101052722A/zh active Pending
- 2005-09-08 NZ NZ554236A patent/NZ554236A/en not_active IP Right Cessation
- 2005-09-08 EP EP05789661.5A patent/EP1794299B1/en not_active Expired - Lifetime
- 2005-09-08 AU AU2005284136A patent/AU2005284136B2/en not_active Expired
- 2005-09-08 CA CA 2580009 patent/CA2580009C/en not_active Expired - Lifetime
- 2005-09-08 WO PCT/EP2005/054450 patent/WO2006029985A2/en not_active Ceased
- 2005-09-08 BR BRPI0515436-7A patent/BRPI0515436A/pt not_active IP Right Cessation
- 2005-09-08 CN CN201310409070.8A patent/CN103555644B/zh not_active Expired - Lifetime
- 2005-09-08 JP JP2007531743A patent/JP5301832B2/ja not_active Expired - Lifetime
- 2005-09-08 KR KR1020107017286A patent/KR20100101689A/ko not_active Ceased
- 2005-09-14 US US11/226,795 patent/US20060063232A1/en not_active Abandoned
- 2005-09-19 AR ARP050103886 patent/AR050649A1/es not_active Application Discontinuation
-
2007
- 2007-03-14 IL IL181919A patent/IL181919A/en not_active IP Right Cessation
-
2008
- 2008-10-28 US US12/259,662 patent/US9297014B2/en active Active
-
2011
- 2011-01-21 AR ARP110100203 patent/AR079958A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070059130A (ko) | 2007-06-11 |
| AU2005284136B2 (en) | 2011-07-14 |
| KR20100101689A (ko) | 2010-09-17 |
| JP2008512998A (ja) | 2008-05-01 |
| WO2006029985A2 (en) | 2006-03-23 |
| BRPI0515436A (pt) | 2008-07-22 |
| CA2580009A1 (en) | 2006-03-23 |
| EP1794299B1 (en) | 2015-09-02 |
| TWI311152B (en) | 2009-06-21 |
| AU2005284136A1 (en) | 2006-03-23 |
| US9297014B2 (en) | 2016-03-29 |
| AR079958A2 (es) | 2012-02-29 |
| TW200621985A (en) | 2006-07-01 |
| US20060063232A1 (en) | 2006-03-23 |
| WO2006029985A3 (en) | 2006-07-27 |
| AR050649A1 (es) | 2006-11-08 |
| CN101052722A (zh) | 2007-10-10 |
| KR101023066B1 (ko) | 2011-03-24 |
| CA2580009C (en) | 2013-12-17 |
| JP5301832B2 (ja) | 2013-09-25 |
| US20090263861A1 (en) | 2009-10-22 |
| CN103555644A (zh) | 2014-02-05 |
| CN103555644B (zh) | 2018-06-01 |
| EP1794299A2 (en) | 2007-06-13 |
| IL181919A (en) | 2012-04-30 |
| IL181919A0 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9297014B2 (en) | Host-vector system antibiotic-free ColE1 plasmid propagation | |
| Wegerer et al. | Optimization of an E. coli L-rhamnose-inducible expression vector: test of various genetic module combinations | |
| Opdyke et al. | RNase III participates in GadY-dependent cleavage of the gadX-gadW mRNA | |
| Williams et al. | Generic plasmid DNA production platform incorporating low metabolic burden seed‐stock and fed‐batch fermentation processes | |
| Parales et al. | Regulation of the pcaIJ genes for aromatic acid degradation in Pseudomonas putida | |
| Cranenburgh et al. | Effect of plasmid copy number and lac operator sequence on antibiotic-free plasmid selection by operator-repressor titration in Escherichia coli | |
| US20190032048A1 (en) | Improved cloning and expression vectors and systems | |
| CA2358263A1 (en) | Methods | |
| KR102688555B1 (ko) | CRISPR/Cpf1 시스템을 기반으로 한 유전체 단일 염기 편집 방법 및 이의 용도 | |
| JPH0753111B2 (ja) | 条件非制御の複製挙動を持つプラスミド | |
| PL222067B1 (pl) | Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor ekspresyjny, komórka prokariotycznego gospodarza zawierająca wektor ekspresyjny, szczep bakteryjny oraz sposób wytwarzania polipeptydu | |
| EP1924693B1 (en) | Hybrid portable origin of replication plasmids | |
| US20250179506A1 (en) | Microorganism strain for antibiotic-free plasmid-based fermentation and method for generation thereof | |
| US20110269184A1 (en) | Method for controlling plasmid copy number in e.coli | |
| US20030003525A1 (en) | Novel promoter of gene expression | |
| JP2007151542A (ja) | 相同組換えによる目的遺伝子のクローニング及び発現方法 | |
| MX2007003110A (en) | Host-vector system for antibiotic-free cole1 plasmid propagation | |
| US8999672B2 (en) | Compositions and processes for improved plasmid DNA production | |
| Zh et al. | Design and study on characteristics of auto-and smoothly regulated genetic element O3/PlacUV5/Olac→ lacI | |
| KR20250042179A (ko) | CRISPR-Cas9-기반의 플라스미드 DNA 주형의 선형화 | |
| RU2312146C1 (ru) | Вектор на основе репликона бактериофага n15 и рекомбинантный вектор для регулируемой экспрессии целевого гена в клетках escherichia coli, штамм escherichia coli, обеспечивающий возможность регуляции числа копий вектора, и система экспрессии | |
| Geist et al. | TraM protein of plasmid R1: in vitro selection of the target region reveals two consensus 7 bp binding motifs spaced by a 4 bp linker of defined sequence | |
| CN120400098A (zh) | 一种Cas12核酸酶突变体及其应用 | |
| Zolotukhina et al. | Mutational Analysis of a Leader Region of the Escherichia coli ribB Gene | |
| HK1086297A1 (zh) | 具有条件性复制起点的环形dna分子及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2016 BY DENNEMEYER + CO Effective date: 20150820 |
|
| LAPS | Patent lapsed |